Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax Inc (NQ: NVAX )

9.350 -0.260 (-2.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
59 60 Next >
5 Stocks With Short Interest Over 40%: Possible Short Squeeze Plays
Short selling can be profitable, but sometimes when the stock moves against short sellers and begins to rise, the short sellers jump in to buy shares to cover their positions, creating what is called a... 
Via Talk Markets
Are You Kidding Me? 3 Meme Stocks You Should Have Already Sold
Be sure to sell these meme stocks as they represent fundamentally weak businesses that will continue to erode in value. 
Via InvestorPlace
Time to Buy These 3 Stocks That Just Hit a 52-Week Low?
Sometimes buying stocks at a 52-week low is a chance to buy a good company at great prices but you need to see if the business is busted. 
Via InvestorPlace
3 Turnaround Stocks With 151% to 600% Upside in 2024, According to Select Wall Street Analysts
High-water price targets from select analysts imply triple-digit gains in the new year for three former highfliers. 
Via The Motley Fool
7 Magnificent Stocks That Can Double Your Money in 2024
Triple-digit returns could be just a click of the buy button away. 
Via The Motley Fool
What's Going On With Novavax Stock?
Novavax Inc (NASDAQ: NVAX) shares are volatile. 
Via Benzinga
Is Novavax Stock a Buy Now?
The company's shares may look cheap on the surface, but don't be too quick to jump in. 
Via The Motley Fool
What's Going On With Novavax Stock Tuesday?
Novavax Inc (NASDAQ: NVAX) shares are trading higher Tuesday. 
Via Benzinga
Smart Shorts: 7 Meme Stocks to Bet Against in 2024
These seven meme stocks have surged as speculators declare "the coast is clear," but a big reversal for each of them may be forthcoming. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Heavily Shorted Stocks That Still Won’t See a Squeeze
These are the heavily shorted stocks to avoid as they are likely to continue trending lower on the back of very weak fundamentals. 
Via InvestorPlace
3 Meme Stocks That Could Fade Away in 2024
These are the meme stocks to avoid or sell as they have extremely weak fundamentals and are unlikely to recover from a financial perspective. 
Via InvestorPlace
What's Going On With Novavax Hitting A New 52-Week Low?
Novavax Inc (NASDAQ: NVAX) shares are trading lower by 4.4% to $5.08 Wednesday afternoon. 
Via Benzinga
Where Will Novavax Be in 3 Years?
Novavax shares have plunged from early pandemic highs. 
Via The Motley Fool
Novavax's Earnings: A Preview
Via Benzinga
This Tech Stock Is 'Too Expensive,' Cramer Says: 'Wait For A Pullback'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Camtek Ltd. 
Via Benzinga
3 Short-Squeeze Stocks That Could Take Off Before Year-End
These three short-squeeze stocks are seeing high short interest. They each could see a year-end short squeeze and notable market moves. 
Via InvestorPlace
Could a Short Squeeze Be Coming for These 3 Heavily Shorted Stocks?
Should investors expect any of these stocks to turn their fortunes around next year? 
Via The Motley Fool
Novavax Prepares Further Cost Cuts To Better Align With Demand-Challenged COVID-19 Vaccine Market
Novavax Inc (NASDAQ: NVAX) reported Q3 revenue of $187 million, compared to $735 million in the same period in 2022, beating the  
Via Benzinga
Exposures COVID-19
Wall Street To Snap Longest Winning Streak Since 2021 Today? Earnings, Bond Yields In Focus Ahead Of Powell's Speech
The stock market’s momentum appears to be waning, and futures suggest a mixed opening for Thursday. Earnings reports have generally been positive, with companies like Walt Disney Co. 
Via Benzinga
Down 75% From Its High, Has Novavax Stock Become Too Cheap to Pass Up?
It won't be easy for this company to win back investors, as the business faces some big challenges. 
Via The Motley Fool
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
The company issued below-consensus sales views for 2023 and 2024. 
Via Investor's Business Daily
7 Dangerous Stocks to Avoid No Matter What
Despite arguments to the contrary, stay away from each of these seven stocks to avoid, as each carries substantial downside risk. 
Via InvestorPlace
Top 6 Nasdaq Short Squeeze Play Stocks
The following are some heavily shorted tech stocks that may be worth considering. 
Via Talk Markets
Pfizer Reportedly Hikes Paxlovid Price To $1,390 — More Than Double What The Government Paid
The transition to the commercial market is planned for 2024 and could bolster sales. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Do These 5 Words From Pfizer Mean Trouble for Novavax?
Coronavirus vaccine sales could represent recurrent annual revenue for Novavax and rivals. 
Via The Motley Fool
Exposures COVID-19
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. 
Via Benzinga
Bitcoin's ETF Approval Rumor, Pfizer Slashes Annual Outlook, Activist Shareholder Shakes Up News Corp's Status Quo: Today's Top Stories
Benzinga Bitcoin Spiked On False ETF Approval Rumor 
Via Benzinga
Topics ETFs
Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 Billion
Pfizer cut about $9 billion from its sales expectations for Covid products this year. 
Via Investor's Business Daily
Exposures COVID-19
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
59 60 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.